TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation - An intravenous nPA for treatment of infarcting myocardium early II trial substudy
TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation - An intravenous nPA for treatment of infarcting myocardium early II trial substudy
复制标题
DOI：
10.1161/01.cir.102.17.2031
复制
发表时间：
2000-10-24
期刊：
影响因子：
37.8
通讯作者：
Braunwald, E
中科院分区：
文献类型：
--
作者：
Morrow, DA;Antman, EM;Braunwald, E
背景-ST段抬高型心肌梗死（STEMI）患者的死亡风险存在相当大的差异，复杂的多变量模型识别独立的预测因子，并量化其对死亡风险的相对贡献，但过于繁琐，不易于在临床实践中应用。方法和结果-我们开发并评估了一种方便的床边临床风险评分，用于预测30天的死亡率，在纤维蛋白溶解，符合条件的STEMI患者，STEMI的心肌梗死溶栓（TIMI）风险评分创建为根据静脉内nPA治疗早期心肌梗死II试验（n=14 114）中logistic回归分析的校正比值比加权的死亡率独立预测因素的简单算术和。平均30天死亡率为6.7%。10个基线变量，占多变量模型预测能力的97%，构成了TIMI风险评分。风险评分显示死亡率分级增加>40倍，评分范围从0到>8（P
Background-Considerable variability in mortality risk exists among patients with ST-elevation myocardial infarction (STEMI), Complex multivariable models identify independent predictors and quantify their relative contribution to mortality risk but are too cumbersome to be readily applied in clinical practice.Methods and Results-We developed and evaluated a convenient bedside clinical risk score for predicting 30-day mortality at presentation of fibrinolytic-eligible patients with STEMI, The Thrombolysis in Myocardial Infarction (TIMI) risk score for STEMI was created as the simple arithmetic sum of independent predictors of mortality weighted according to the adjusted odds ratios from logistic regression analysis in the Intravenous nPA for Treatment of Infarcting Myocardium Early II trial (n=14 114). Mean 30-day mortality was 6.7%. Ten baseline variables, accounting for 97% of the predictive capacity of the multivariate model, constituted the TIMI risk score. The risk score showed a >40-fold graded increase in mortality, with scores ranging from 0 to >8 (P